Dimerix Secures Licensing Agreement with FUSO for Kidney Disease Treatment

March 04, 2025 11:00 AM AEDT | By Team Kalkine Media

Google News:

Dimerix Secures Licensing Agreement with FUSO for Kidney Disease Treatment — Image source: Shutterstock

Recent News

Sitio Royalties downgraded after Viper Energy agrees to acquire co for...

New Study: Wildfires Cause Months-Long Delays in Medical Care for At-R...

Wall Street analysts initiate coverage of eToro

NVIDIA stock gains as Huang kicks off European tour with UK his first...

Highlights:

Dimerix receives an upfront payment from FUSO Pharmaceutical Industries for the development and commercialization of DMX-200.

The agreement includes additional development and sales milestone payments, along with royalties on net sales.

Additional licensing agreements with Advanz Pharma and Taiba expand commercialization across multiple regions.

Dimerix (ASX:DXB), a biopharmaceutical company, has entered a licensing agreement with Japan-based FUSO Pharmaceutical Industries for the development and commercialization of DMX-200. The company has received an initial payment as part of the agreement, which focuses on treating focal segmental glomerulosclerosis (FSGS), a serious kidney condition.

Development and Commercialization Milestones

The agreement grants FUSO exclusive rights to commercialize DMX-200 within Japan. Additional payments will be provided upon reaching key development milestones, alongside financial incentives tied to sales performance. A structured royalty percentage is included in the agreement based on net sales upon successful commercialization.

Clinical Progress and Expansion in Japan

The ACTION3 phase III clinical trial, designed to evaluate DMX-200’s efficacy in treating FSGS, is progressing with site identification in Japan. The trial follows a double-blind, placebo-controlled format. Interim data from the study is anticipated within the next eighteen months. The condition affects both children and adults, leading to progressive kidney damage.

Broader Licensing Agreements

Beyond Japan, Dimerix has secured additional licensing agreements to expand DMX-200’s reach. A collaboration with Advanz Pharma includes territories such as Europe, Canada, and Australasia, while an agreement with Taiba extends into Middle Eastern regions. Collectively, these partnerships contribute to the broader commercialization of the treatment.

Regulatory Designations and Market Presence

DMX-200 has been granted Orphan Drug Designation in the United States and Europe, with additional designations in the United Kingdom. These regulatory acknowledgments reinforce the commitment to advancing treatment options for FSGS. Ongoing strategic licensing discussions continue to focus on expanding into other key markets, including the United States and China.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.